Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10778983rdf:typepubmed:Citationlld:pubmed
pubmed-article:10778983lifeskim:mentionsumls-concept:C0033229lld:lifeskim
pubmed-article:10778983lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:10778983lifeskim:mentionsumls-concept:C0012582lld:lifeskim
pubmed-article:10778983lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:10778983lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:10778983lifeskim:mentionsumls-concept:C1660751lld:lifeskim
pubmed-article:10778983pubmed:issue4lld:pubmed
pubmed-article:10778983pubmed:dateCreated2000-8-3lld:pubmed
pubmed-article:10778983pubmed:abstractTextIncubation of drug-resistant human tumor cells with a combination of prochlorperazine and dipyridamole has additive/synergistic effect on the cellular retention and cytotoxicity of doxorubicin. In patients administered a fixed dose of doxorubicin and prochlorperazine with escalating doses of dipyridamole, mean plasma levels of dipyridamole and prochlorperazine achieved were as high as 3.01 +/- 0.41 microm and 0.94 +/- 0.09 microm, respectively. Plasma samples from patients were analyzed in an in vitro assay to monitor the effect on the cellular retention of tritium-labeled daunorubicin in MDR1-transfected P388 cells. In 22 of 49 of the plasma samples analyzed, the daunorubicin in efflux blocking activity was one-half or greater than that of cells incubated with 12.5 microM verapamil, a well-known efflux blocker. These observations suggest that a combination of prochlorperazine and dipyridamole may enhance cellular doxorubicin retention by blocking efflux while reducing normal tissue toxicity and unwanted side effects in vivo.lld:pubmed
pubmed-article:10778983pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:languageenglld:pubmed
pubmed-article:10778983pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:citationSubsetIMlld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10778983pubmed:statusMEDLINElld:pubmed
pubmed-article:10778983pubmed:monthAprlld:pubmed
pubmed-article:10778983pubmed:issn1078-0432lld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:KrishanAAlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:SteinW DWDlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:MoeSSlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:FernandezHHlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:YimYYlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:SridharK SKSlld:pubmed
pubmed-article:10778983pubmed:authorpubmed-author:LyubimovEElld:pubmed
pubmed-article:10778983pubmed:issnTypePrintlld:pubmed
pubmed-article:10778983pubmed:volume6lld:pubmed
pubmed-article:10778983pubmed:ownerNLMlld:pubmed
pubmed-article:10778983pubmed:authorsCompleteYlld:pubmed
pubmed-article:10778983pubmed:pagination1508-17lld:pubmed
pubmed-article:10778983pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:meshHeadingpubmed-meshheading:10778983...lld:pubmed
pubmed-article:10778983pubmed:year2000lld:pubmed
pubmed-article:10778983pubmed:articleTitleSynergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.lld:pubmed
pubmed-article:10778983pubmed:affiliationDepartment of Radiation Oncology, University of Miami Medical School and Sylvester Cancer Center, Florida 33136, USA. akrishan@mednet.med.miami.edulld:pubmed
pubmed-article:10778983pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10778983pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10778983pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10778983pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:10778983pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10778983lld:pubmed